Skip to main content
OpenTrials
Completed

NCT Number: NCT02133339

Single Ascending Dose Study of TRN-157 in Healthy Subjects

This single ascending dose study is to determine and evaluate the safety and tolerability of TRN-157 in approximately 40 healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Cypress, California, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has provided written informed consent
  • The subject is male or female 18 to 65 years of age
  • If the subject or subject's partner is of childbearing potential, a medically acceptable form of contraception will be
  • Non-smoker
  • Good general health
  • Willing to abstain from alcohol, caffeine, and xanthine-containing beverages
  • The subject is compliant and available throughout the entire study period

Exclusion criteria

  • Current diagnosis, as per subject or investigator or screening assessment, of:
  • unstable or uncontrolled disease in any organ system (including cardiovascular) on present therapy
  • history of narrow angle glaucoma
  • history of alcohol abuse within the past 5 years
  • history of smoking within the past 6 months
  • positive result for the alcohol and/or drugs of abuse
  • weight > 100 kg or < 50 kg
  • clinically significant abnormal ECG
  • history of clinically significant (per the Investigator) disease or disorder
  • any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results
  • Abnormal vital signs defined as any of the following:
  • Systolic blood pressure ≥ 140 mmHg
  • Diastolic blood pressure ≥ 90mmHg
  • Heart rate < 40 or > 85 beats per minute
  • Fever or other clinically significant physical exam findings
  • Current or history of clinically significant respiratory disease, including asthma, emphysema, chronic bronchitis, or cystic fibrosis
  • History or current symptom(s) of respiratory tract inflammation
  • Inability to perform reproducible spirometry in accordance with American Thoracic Society (ATS) guidelines
  • Abnormal FEV1, FVC, or FEV1/FVC (FEV1 or FVC < 80% of predicted or FEV1/FVC ratio < 0.7)
  • FEV1 variability > 10% between study visits
  • Female of childbearing potential with a positive serum pregnancy test or currently breastfeeding
  • Currently being treated for hypertension or taking any other medications that affect blood pressure significantly
  • Inability to perform acceptable, quality serial spirometry or any other study procedures
  • Positive screen for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or HIV antibody

Treatment and study plan

TRN-157

Drug

Placebo

Drug

Primary outcomes

  1. Safety and tolerability as determined by number of subjects with adverse events

    Time frame: 1 week

Secondary outcomes

  1. Determination of pharmacokinetic parameters

    Time frame: 1 week

    Area Under the Plasma Concentration-Time Curve from Zero to the Time of the Last Measurable Concentration (AUC0-t)

  2. Determination of pharmacokinetic parameters

    Time frame: 1 week

    Area Under the Plasma Concentration-Time Curve from Zero to Infinity (AUC0-inf)

  3. Determination of pharmacokinetic parameters

    Time frame: 1 week

    Peak Plasma Concentration (Cmax)

  4. Determination of pharmacokinetic parameters

    Time frame: 1 week

    Time to Peak Plasma Concentration (tmax)

  5. Determination of pharmacokinetic parameters

    Time frame: 1 week

    Half-Life (t½)

  6. Determination of pharmacokinetic parameters

    Time frame: 1 week

    Elimination Rate Constant (kel)

  7. Determination of pharmacokinetic parameters

    Time frame: 1 week

    Volume of Distribution at Steady State after Non-IV Administration (Vss/F)

  8. Determination of pharmacokinetic parameters

    Time frame: 1 week

    Total Plasma Clearance after Non-IV Administration (CL/F)

Sponsors and collaborators

Lead sponsor

Theron Pharmaceuticals, Inc.

Industry

Registry information

Official study title

A Phase I, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Nebulized, TRN-157 Inhalation Solution in Healthy Subjects

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
May 8, 2014
Registry last updated
Oct 31, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.